BAFF Antibody

B-cell Activating Factor (BAFF), also known as B-lymphocyte stimulator (BLyS), is a crucial cytokine belonging to the tumor necrosis factor (TNF) family. It plays a significant role in the development, survival, and function of B cells. BAFF is produced by various cell types, including monocytes, macrophages, dendritic cells, and activated T cells .

BAFF is essential for B-cell maturation and survival. It binds to three different receptors: BAFF-R, TACI, and BCMA, each with distinct roles in B-cell physiology . BAFF-R is primarily responsible for the survival of immature and mature B cells, while TACI and BCMA are involved in the regulation of B-cell activation and differentiation .

Mouse anti-human BAFF antibodies are monoclonal antibodies developed in mice that specifically target human BAFF. These antibodies are used in research and clinical settings to study the role of BAFF in various diseases and to develop therapeutic interventions .

Elevated levels of BAFF are associated with several autoimmune diseases, such as Systemic Lupus Erythematosus (SLE) and Sjögren’s syndrome . Excessive BAFF can lead to the survival of autoreactive B cells, contributing to the pathogenesis of these diseases . BAFF-targeted therapies, such as belimumab, have been developed to treat autoimmune conditions by inhibiting BAFF activity .

Research on BAFF has led to the development of various therapeutic strategies targeting BAFF and its receptors. For instance, belimumab, an anti-BAFF monoclonal antibody, is used in the treatment of SLE . Other therapeutic approaches include the use of decoy receptors like atacicept and monoclonal antibodies like tabalumab .